Estrella Immunopharma Files 8-K on Material Agreement
Ticker: ESLAW · Form: 8-K · Filed: Dec 6, 2024 · CIK: 1844417
Sentiment: neutral
Topics: material-agreement, corporate-action
Related Tickers: ESLA
TL;DR
Estrella Immunopharma (ESLA) filed an 8-K on Dec 4th for a material definitive agreement. Details to follow.
AI Summary
Estrella Immunopharma, Inc. filed an 8-K on December 6, 2024, reporting a material definitive agreement entered into on December 4, 2024. The filing also includes financial statements and exhibits. Estrella Immunopharma, Inc. is a biotechnology company focused on biological products, formerly known as TradeUP Acquisition Corp. until February 4, 2021.
Why It Matters
This 8-K filing indicates a significant new agreement for Estrella Immunopharma, which could impact its business operations and financial standing. Investors should review the details of this agreement to understand its implications.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the specifics of this agreement are not yet detailed in the provided filing excerpt.
Key Players & Entities
- Estrella Immunopharma, Inc. (company) — Registrant
- December 4, 2024 (date) — Date of earliest event reported
- December 6, 2024 (date) — Date of report
- TradeUP Acquisition Corp. (company) — Former company name
- February 4, 2021 (date) — Date of name change
FAQ
What is the nature of the material definitive agreement entered into by Estrella Immunopharma, Inc. on December 4, 2024?
The provided excerpt of the 8-K filing states that a material definitive agreement was entered into on December 4, 2024, but does not specify the details of the agreement.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted on December 6, 2024.
What was Estrella Immunopharma, Inc.'s former company name?
Estrella Immunopharma, Inc. was formerly known as TradeUP Acquisition Corp.
On what date did the company change its name from TradeUP Acquisition Corp. to Estrella Immunopharma, Inc.?
The company changed its name on February 4, 2021.
What is Estrella Immunopharma, Inc.'s primary business classification?
Estrella Immunopharma, Inc. is classified under BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) with SIC code 2836.
Filing Stats: 759 words · 3 min read · ~3 pages · Grade level 11.5 · Accepted 2024-12-06 09:12:42
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ESLA The Nasdaq Stock Mar
- $11.50 — of Common Stock at an exercise price of $11.50 ESLAW The Nasdaq Stock Market LLC
- $50 million — ch the Company may sell and issue up to $50 million of its common stock to White Lion from
- $1,000,000 m — h Rapid Purchase remains subject to the $1,000,000 maximum purchase amount applicable to reg
Filing Documents
- ea0223902-8k_estrella.htm (8-K) — 33KB
- ea022390201ex10-1_estrella.htm (EX-10.1) — 36KB
- 0001213900-24-106238.txt ( ) — 294KB
- esla-20241204.xsd (EX-101.SCH) — 4KB
- esla-20241204_def.xml (EX-101.DEF) — 26KB
- esla-20241204_lab.xml (EX-101.LAB) — 36KB
- esla-20241204_pre.xml (EX-101.PRE) — 25KB
- ea0223902-8k_estrella_htm.xml (XML) — 6KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On December 5, 2024, Estrella Immunopharma, Inc. (the " Company ") entered into Amendment No. 2 (the " Amendment ") to the Common Stock Purchase Agreement dated April 20, 2023, as previously amended on April 26, 2023 (the " Purchase Agreement "), with White Lion Capital, LLC (" White Lion "). pursuant to which the Company may sell and issue up to $50 million of its common stock to White Lion from time to time, subject to certain terms and conditions. The Amendment extends the term of the Purchase Agreement from December 30, 2024 to December 30, 2025. Additionally, the Amendment adds a new "Rapid Purchase" mechanism allowing for expedited settlement of share purchases compared to the standard purchase process under the original agreement. Under this new mechanism, the Company may deliver Rapid Purchase Notices to White Lion by 11:00 a.m. New York time on any business day when the Company's common stock is not trading on an over-the-counter market, with concurrent delivery of the subject shares via DWAC to White Lion's brokerage account. The purchase price for Rapid Purchases will be the lowest traded price of the Company's common stock on the Rapid Purchase Notice date, with White Lion required to wire payment by 5:00 p.m. New York time on the following business day. For Rapid Purchases, the maximum number of shares the Company can require White Lion to purchase is limited to the lesser of (i) 20% of the average daily trading volume or (ii) the investment limit divided by the highest closing price over the previous five business days, though White Lion may waive these limitations. Each Rapid Purchase remains subject to the $1,000,000 maximum purchase amount applicable to regular purchases under the Purchase Agreement. The foregoing description of the Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, which is filed as Exhibit 10.1 to this
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits 10.1 Amendment No. 2 to Common Stock Purchase Agreement, dated December 4, 2024, by and between Estrella Immunopharma, Inc. and White Lion Capital, LLC 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Estrella Immunopharma, Inc. By: /s/ Peter Xu Name: Peter Xu Title: Chief Financial Officer Date: December 6, 2024 2